All In Biotech

Drug Trial Radar · NCT06748053

A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma

A Multicentre, Randomized, Double-Blind, Placebo Controlled, Dose Finding, Parallel Group, Phase 2 Study of an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 307 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

307

Actual

Start

Feb 10, 2025

Primary completion

Jul 14, 2026

Study completion Sep 9, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Dec 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is trying to find the right dose of a long-lasting medicine called GSK5784283 for people with asthma that remains uncontrolled even though they are using regular asthma treatments. GSK5784283 blocks the action of an inflammatory protein called TSLP that may be contributing to your asthma. The study will be conducted in two parts - Part A (dose finding phase) and Part B (extended dosing phase). Part A will assess the lung function, asthma control, participant safety and certain markers of asthma inflammation in the air you breath out and in your blood. Part B will assess the safety and long-term effects of the repeated or single doses of GSK5784283.

Conditions

  • Asthma

Interventions

  • GSK5784283Drug

    GSK5784283 will be administered.

  • PlaceboDrug

    Placebo will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Change from baseline in the fraction of exhaled nitric oxide (FeNo)Time frame: Baseline (Day 1) and at 2, 4, 8,12, 20 and 26 weeks

Locations

137 sites in 9 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Modesto, California

  • GSK Investigational Site

    Redding, California

  • GSK Investigational Site

    Riverside, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    San Jose, California

  • GSK Investigational Site

    Colorado Springs, Colorado

  • GSK Investigational Site

    Lakewood, Colorado

  • GSK Investigational Site

    Wheat Ridge, Colorado

  • GSK Investigational Site

    New Haven, Connecticut

  • GSK Investigational Site

    Aventura, Florida

  • GSK Investigational Site

    Hialeah, Florida

  • GSK Investigational Site

    Lake Worth, Florida

  • GSK Investigational Site

    Leesburg, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Plantation, Florida

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    Skokie, Illinois

  • GSK Investigational Site

    Shreveport, Louisiana

  • GSK Investigational Site

    Lathrup Village, Michigan

  • GSK Investigational Site

    Warren, Michigan

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Omaha, Nebraska

  • GSK Investigational Site

    The Bronx, New York

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    DuBois, Pennsylvania

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Wyomissing, Pennsylvania

  • GSK Investigational Site

    Warwick, Rhode Island

  • GSK Investigational Site

    Greenville, South Carolina

  • GSK Investigational Site

    Spartanburg, South Carolina

  • GSK Investigational Site

    Knoxville, Tennessee

  • GSK Investigational Site

    Boerne, Texas

Showing 40 of 137 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.